IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

被引：52
|
作者：
Emens, L. A. [1 ]
Adams, S. [2 ]
Barrios, C. H. [3 ]
Dieras, V. C. [4 ]
Iwata, H. [5 ]
Loi, S. [6 ]
Rugo, H. S. [7 ]
Schneeweiss, A. [8 ]
Winer, E. P. [9 ]
Patel, S. [10 ]
Henschel, V. [11 ]
Swat, A. [12 ]
Kaul, M. [13 ]
Molinero, L. [14 ]
Chui, S. Y. [15 ]
Schmid, P. [16 ]
机构：
[1] UPMC Hillman Canc Ctr, Dept Med Hematol Oncol, Pittsburgh, PA USA
[2] NYU, Langone Med Ctr, Sch Med, New York, NY USA
[3] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Invest Ctr, Porto Alegre, RS, Brazil
[4] Ctr Eugene Marquis, Med Oncol, Rennes, France
[5] Aichi Canc Ctr Hosp, Breast Oncol, Nagoya, Aichi, Japan
[6] Peter MacCallum Canc Ctr, Div Res, Translat Breast Canc Genom Lab, Melbourne, Vic, Australia
[7] UCSF, Helen Diller Family Comprehens Canc Ctr, Breast Dept, San Francisco, CA USA
[8] Univ Hosp Heidelberg, German Canc Res Ctr, Heidelberg, Germany
[9] Dana Farber Canc Inst, Med, Boston, MA 02115 USA
[10] Genentech Inc, Med Oncol, San Francisco, CA USA
[11] Genentech Inc, Biostat, San Francisco, CA USA
[12] F Hoffmann La Roche, Clin Sci, Basel, Switzerland
[13] F Hoffmann La Roche, Canc Immunotherapy Clin Safety, Basel, Switzerland
[14] Genentech Inc, Oncol Biomarker Dev, San Francisco, CA 94080 USA
[15] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[16] Queen Mary Univ London, Barts Canc Inst, London, England
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.2244
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA16
引用
收藏
页码：S1148 / S1148
页数：1
相关论文
共 50 条
  • [41] Atezolizumab (atezo) plus nab-paclitaxel (nab-pac) in metastatic triple-negative breast cancer (mTNBC): 2-year update from a ph Ib trial
    Pohlmann, Paula R.
    Diamond, Jennifer R.
    Hamilton, Erika
    Tolaney, Sara M.
    Zhang, Wei
    Iizuka, Koho
    Foster, Paul
    Molinero, Luciana
    Funke, Roel
    Adams, Sylvia
    CANCER RESEARCH, 2018, 78 (13)
  • [42] IMpower131: Final OS Results of Carboplatin plus Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC
    Jotte, R.
    Cappuzzo, F.
    Vynnychenko, I.
    Stroyakovskiy, D.
    Rodriguez Abreu, D.
    Hussein, M.
    Soo, R.
    Conter, H.
    Kozuki, T.
    Huang, K.
    Graupner, V.
    Sun, S.
    Hoang, T.
    Jessop, H.
    Mccleland, M.
    Ballinger, M.
    Sandler, A.
    Socinski, M.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S243 - S244
  • [43] Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
    Chisaki, Yugo
    Kuwada, Yoshiki
    Matsumura, Chikako
    Yano, Yoshitaka
    CLINICAL DRUG INVESTIGATION, 2021, 41 (04) : 381 - 389
  • [44] Cost-effectiveness Analysis of Atezolizumab Plus Nab-Paclitaxel for Advanced PD-L1 Positive Triple-Negative Breast Cancer in Japan
    Yugo Chisaki
    Yoshiki Kuwada
    Chikako Matsumura
    Yoshitaka Yano
    Clinical Drug Investigation, 2021, 41 : 381 - 389
  • [45] Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer: a multicenter, randomized, phase II study
    Jin, Min
    Liu, Hong-Li
    Xue, Jun
    Ma, Hong
    Liu, Jun-Li
    Lin, Zhen-Yu
    Wang, Jing
    Bao, Le-Qun
    Luo, Zhi-Guo
    Yu, Xiong-Jie
    Li, Shuang
    Hu, Jian-Li
    Zhang, Tao
    ONCOLOGIST, 2024, 29 (10): : e1406 - e1418
  • [46] Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple negative breast cancer (mTNBC).
    Adams, Sylvia
    Diamond, Jennifer Robinson
    Hamilton, Erika Paige
    Pohlmann, Paula Raffin
    Tolaney, Sara M.
    Molinero, Luciana
    He, Xian
    Waterkamp, Daniel
    Funke, Roel Peter
    Powderly, John D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [47] Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer
    Wang, Hanwen
    Ma, Huilin
    Sove, Richard J.
    Emens, Leisha A.
    Popel, Aleksander S.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (02)
  • [48] randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Saha, Poornima
    Rampurwala, Murtuza M.
    Kamaraju, Sailaja
    Hahn, Olwen Mary
    Howard, Frederick Matthew
    Fleming, Gini F.
    Matossian, Margarite
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne D.
    Nanda, Rita
    Stringer-Reasor, Erica Michelle
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [49] Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: the BIBABRAX study
    Jaime Feliu
    Mónica Jorge Fernández
    Teresa Macarulla
    Bartomeu Massuti
    Ana Albero
    José Federico González González
    Guillermo Quintero-Aldana
    Juan Ignacio Delgado-Mingorance
    Ana Fernández Montes
    Carmen García Piernavieja
    Manuel Valladares-Ayerbes
    Ana María López Muñoz
    Rebeca Mondéjar Solís
    Pilar Vicente
    Esther Casado Gonzalez
    Irene González Cebrián
    Guillermo López-Vivanco
    Cancer Chemotherapy and Pharmacology, 2021, 87 : 543 - 553
  • [50] A randomized phase II trial of nab-paclitaxel with or without mifepristone for advanced triple-negative breast cancer
    Chen, Nan
    Matossian, Margarite
    Saha, Poornima
    Rampurwala, Murtuza
    Kamaraju, Salaija
    Hahn, Olwen
    Howard, Frederick M.
    Fleming, Gini F.
    Freeman, Jincong Q.
    Karrison, Theodore
    Conzen, Suzanne
    Nanda, Rita
    Stringer-Reasor, Erica M.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, : 111 - 119
12345